Takeda's AI-crafted psoriasis pill succeeds in late-stage studies [Yahoo! Finance]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Yahoo! Finance
More than half ?the plaque psoriasis patients across the studies showed clear or almost clear skin after ?16 weeks of treatment with the once-daily drug, zasocitinib, the company said. Takeda plans to file marketing applications with the U.S. Food and Drug Administration and other regulatory authorities in 2026. If approved, zasocitinib would join a ?crowded plaque psoriasis market ?featuring well-established oral rivals like Bristol Myers' Sotyktu and Amgen's Otezla, plus injectables including Johnson & Johnson's Tremfya, AbbVie's ?Skyrizi, and Novartis' Cosentyx. Takeda's pill offers a convenient daily pill alternative alongside Sotyktu and Otezla in a market dominated by injectable drugs for treating plaque psoriasis, ?in which red, scaly patches occur on the skin due ?to an overactive immune system. The company is banking on the blockbuster potential of zasocitinib to help fill a revenue gap it faces after its inflammatory bowel disease drug Entyvio loses key patents at t
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- Unlock Health Appoints Jamie Mermelstein as Vice President of Digital Experience [Yahoo! Finance]Yahoo! Finance
- Johnson & Johnson (NYSE:JNJ) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..MarketBeat
- Johnson & Johnson Receives FDA Approval for TRUFILL n-BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural HematomaPR Newswire
- Johnson & Johnson: Valuation Premium Justified By Accelerating Growth And Mix Premiumization [Seeking Alpha]Seeking Alpha
- VARIPULSE???????????????????SECURE?????????VARIPURE? ?????????? [CNET News]CNET News
JNJ
Earnings
- 10/14/25 - Beat
JNJ
Sec Filings
- 12/11/25 - Form 4
- 12/11/25 - Form 4
- 12/11/25 - Form 4
- JNJ's page on the SEC website